Indexat a

Llicència i ús

Citacions

Altmetrics

Anàlisi d'autories institucional

Guerrero, Maria GamoAutor o coautorCarrera, CristinaAutor o coautorNavarro, Miguel LovaAutor o coautorPodlipnik, SebastianAutor o coautorMascaro Jr, Jose ManuelAutor (correspondència)

Compartir

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series

Publicat a:British Journal Of Dermatology. 192 (3): 501-509 - 2024-12-02 192(3), DOI: 10.1093/bjd/ljae403

Autors: Planella-Fontanillas N; Bosch-Amate X; Jiménez Antón A; Moreno-Vílchez C; Guerrero MG; Del Mar Blanes Martínez M; Ballester Martínez MA; Bassas-Freixas P; Castaño Fernández JL; Estébanez Corrales A; Suarez Fernández R; Santos Alarcón S; Alonso AB; Torrent M; Ballano Ruiz A; Collantes Rodríguez C; España A; Fonseca Capdevila E; Faure IG; Hernández Fernández CP; Melgosa Ramos FJ; Spertino J; Zaragoza Ninet V; Armillas L; Bielsa I; Carrera C; Rafat ME; Fulgencio Barbarin J; Fernandez Vela J; Lova Navarro M; Callizo CM; Martín-Sala S; Ojeda R; Amer MEP; Puigdollers AS; Pujol RM; Podlipnik S; Mascaró JM Jr; Curto-Barredo L

Afiliacions

Resum

Background Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable.Objectives Evaluate the effectiveness and safety of dupilumab in the treatment of BP.Methods A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300 mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator's Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed.Results The study included 103 patients with a median age of 77.3 years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments.Conclusions Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes. In this ambispective multicentre study, dupilumab effectively and safely manages bullous pemphigoid, achieving high remission rates and reducing the need for corticosteroids. Early initiation and exclusive skin involvement predict better outcomes.

Paraules clau